Cargando…
Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action
Looking for new metal-based anticancer treatments, in recent years many ruthenium complexes have been proposed as effective and safe potential drugs. In this context we have recently developed a novel approach for the in vivo delivery of Ru(III) complexes, preparing stable ruthenium-based nucleolipi...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368645/ https://www.ncbi.nlm.nih.gov/pubmed/28349991 http://dx.doi.org/10.1038/srep45236 |
_version_ | 1782517966014775296 |
---|---|
author | Irace, Carlo Misso, Gabriella Capuozzo, Antonella Piccolo, Marialuisa Riccardi, Claudia Luchini, Alessandra Caraglia, Michele Paduano, Luigi Montesarchio, Daniela Santamaria, Rita |
author_facet | Irace, Carlo Misso, Gabriella Capuozzo, Antonella Piccolo, Marialuisa Riccardi, Claudia Luchini, Alessandra Caraglia, Michele Paduano, Luigi Montesarchio, Daniela Santamaria, Rita |
author_sort | Irace, Carlo |
collection | PubMed |
description | Looking for new metal-based anticancer treatments, in recent years many ruthenium complexes have been proposed as effective and safe potential drugs. In this context we have recently developed a novel approach for the in vivo delivery of Ru(III) complexes, preparing stable ruthenium-based nucleolipidic nanoaggregates endowed with significant antiproliferative activity. Herein we describe the cellular response to our ruthenium-containing formulations in selected models of human breast cancer. By in vitro bioscreens in the context of preclinical studies, we have focused on their ability to inhibit breast cancer cell proliferation by the activation of the intrinsic apoptotic pathway, possibly via mitochondrial perturbations involving Bcl-2 family members and predisposing to programmed cell death. In addition, the most efficient ruthenium-containing cationic nanoaggregates we have hitherto developed are able to elicit both extrinsic and intrinsic apoptosis, as well as autophagy. To limit chemoresistance and counteract uncontrolled proliferation, multiple cell death pathways activation by metal-based chemotherapeutics is a challenging, yet very promising strategy for targeted therapy development in aggressive cancer diseases, such as triple-negative breast cancer with limited treatment options. These outcomes provide valuable, original knowledge on ruthenium-based candidate drugs and new insights for future optimized cancer treatment protocols. |
format | Online Article Text |
id | pubmed-5368645 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-53686452017-03-30 Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action Irace, Carlo Misso, Gabriella Capuozzo, Antonella Piccolo, Marialuisa Riccardi, Claudia Luchini, Alessandra Caraglia, Michele Paduano, Luigi Montesarchio, Daniela Santamaria, Rita Sci Rep Article Looking for new metal-based anticancer treatments, in recent years many ruthenium complexes have been proposed as effective and safe potential drugs. In this context we have recently developed a novel approach for the in vivo delivery of Ru(III) complexes, preparing stable ruthenium-based nucleolipidic nanoaggregates endowed with significant antiproliferative activity. Herein we describe the cellular response to our ruthenium-containing formulations in selected models of human breast cancer. By in vitro bioscreens in the context of preclinical studies, we have focused on their ability to inhibit breast cancer cell proliferation by the activation of the intrinsic apoptotic pathway, possibly via mitochondrial perturbations involving Bcl-2 family members and predisposing to programmed cell death. In addition, the most efficient ruthenium-containing cationic nanoaggregates we have hitherto developed are able to elicit both extrinsic and intrinsic apoptosis, as well as autophagy. To limit chemoresistance and counteract uncontrolled proliferation, multiple cell death pathways activation by metal-based chemotherapeutics is a challenging, yet very promising strategy for targeted therapy development in aggressive cancer diseases, such as triple-negative breast cancer with limited treatment options. These outcomes provide valuable, original knowledge on ruthenium-based candidate drugs and new insights for future optimized cancer treatment protocols. Nature Publishing Group 2017-03-28 /pmc/articles/PMC5368645/ /pubmed/28349991 http://dx.doi.org/10.1038/srep45236 Text en Copyright © 2017, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Irace, Carlo Misso, Gabriella Capuozzo, Antonella Piccolo, Marialuisa Riccardi, Claudia Luchini, Alessandra Caraglia, Michele Paduano, Luigi Montesarchio, Daniela Santamaria, Rita Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action |
title | Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action |
title_full | Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action |
title_fullStr | Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action |
title_full_unstemmed | Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action |
title_short | Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action |
title_sort | antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368645/ https://www.ncbi.nlm.nih.gov/pubmed/28349991 http://dx.doi.org/10.1038/srep45236 |
work_keys_str_mv | AT iracecarlo antiproliferativeeffectsofrutheniumbasednucleolipidicnanoaggregatesinhumanmodelsofbreastcancerinvitroinsightsintotheirmodeofaction AT missogabriella antiproliferativeeffectsofrutheniumbasednucleolipidicnanoaggregatesinhumanmodelsofbreastcancerinvitroinsightsintotheirmodeofaction AT capuozzoantonella antiproliferativeeffectsofrutheniumbasednucleolipidicnanoaggregatesinhumanmodelsofbreastcancerinvitroinsightsintotheirmodeofaction AT piccolomarialuisa antiproliferativeeffectsofrutheniumbasednucleolipidicnanoaggregatesinhumanmodelsofbreastcancerinvitroinsightsintotheirmodeofaction AT riccardiclaudia antiproliferativeeffectsofrutheniumbasednucleolipidicnanoaggregatesinhumanmodelsofbreastcancerinvitroinsightsintotheirmodeofaction AT luchinialessandra antiproliferativeeffectsofrutheniumbasednucleolipidicnanoaggregatesinhumanmodelsofbreastcancerinvitroinsightsintotheirmodeofaction AT caragliamichele antiproliferativeeffectsofrutheniumbasednucleolipidicnanoaggregatesinhumanmodelsofbreastcancerinvitroinsightsintotheirmodeofaction AT paduanoluigi antiproliferativeeffectsofrutheniumbasednucleolipidicnanoaggregatesinhumanmodelsofbreastcancerinvitroinsightsintotheirmodeofaction AT montesarchiodaniela antiproliferativeeffectsofrutheniumbasednucleolipidicnanoaggregatesinhumanmodelsofbreastcancerinvitroinsightsintotheirmodeofaction AT santamariarita antiproliferativeeffectsofrutheniumbasednucleolipidicnanoaggregatesinhumanmodelsofbreastcancerinvitroinsightsintotheirmodeofaction |